Issue link: http://deals.uberflip.com/i/1533898
MANUFACTURER AND E‐COMMERCE OF PROPRIETARY DIETARY SUPPLEMENTS New Jersey #67672 BUSINESS HIGHLIGHTS Founded in 2020, the Company is a manufacturer and e‐commerce seller of proprietary dietary supplements for humans and pets. The Company's mix of seven products encompass a full spectrum of supplements providing comprehensive immune and metabolic health, gut, and microbiome support. The products have been sold since 2002 when they were introduced to the market by a predecessor. The Company is headquartered in New Jersey and is relocatable. The Company's products are manufactured using the Company's proprietary manufacturing process. Their efficacy is validated by decades of research and pre‐clinical and clinical studies. The studies confirm that the products' acve ingredient works as an immunomodulator that regulates processes of inflammaon and allergy responses. It acvates the mechanisms involved in anviral protecon like interferons and immunoglobulins and can help to avoid anbiocs by eliminang pathogenic bacteria. It can also serve as a probioc and prebioc by acvang the growth of beneficial microflora, acng essenally as mulple products in one package. Xavier Staggs Senior M&A Advisor Email: xstaggs@generaonal.com Phone: 304‐617‐8007 INVESTMENT BANK OF THE YEAR 2016 - 2017 - 2018 DISCLAIMER: All informaon contained in this document has been provided by the subject company to Generaonal Equity and while believed to be correct has not been verified. Accordingly, Generaonal Equity makes no representaons or warranes as to the accuracy and truthfulness of such informaon. The recipient hereof acknowledges that Generaonal Equity shall not be liable for any loss or injury suffered by said recipient in any way connected to the delivery by Genera‐ onal Equity of this document. At all mes Generaonal Equity and/or its affiliate network members are agents for the seller and not for the buyer. Generaonal Equity's fees are paid by the seller. REVENUE / EBITDA Generaonal Equity 125 Park Avenue , 25th Floor New York, NY 10017 SIGN NDA ► $2.8M 2024 Revenue $671K 2024 EBITDA $2.0M 2023 Revenue $457K 2023 EBITDA CUSTOMER MARKETS REVENUE SOURCES INVESTMENT APPEAL Outstanding Growth Opportunies. There are several opportunies for the Company to significantly increase revenue and profit, including leveraging its proven reputaon based on the efficacy of products to pursue and penetrate new and exisng markets. These opportunies are easily aainable given the appropriate investments in capital and human resources. Proprietary Products. To protect its intellectual property, the Company and its shareholders have spent considerable me and investment in developing new immune and dietary supplements based on the most recent scienfic approach. With proprietary strains, the Company will connue to lead the metabioc/postbiocs/lysate market and bring new formulaons for sale, enhancing customer value. Internaonal Reach. The Company has sold products to customers across the United States and internaonally. Approximately 23% of sales came from resellers and individuals across 59 countries outside the United States. Strong Historical Sales Growth. Historical sales have grown from $852,000 in 2021 to $2,800,000 in the fiscal year ending December 31, 2024, represenng a compound annual growth rate of 48.7%. Sales have grown consistently year over year in the historical period since 2021. Modest Ongoing Capital Investment Requirements. The need for capital expenditure is minimal moving forward. Capital expenditures for vehicles, and office furniture, fixtures and equipment are conservavely projected at approximately $15,000 per annum to support connued operaonal efficiency. Minimal Capital Expenditures. Over this historical period, the Company capitalized no investment in fixed assets on the balance sheet. Given the Company's service‐based operaons, the future need for capital expenditures is low. The Company averaged annual capital expenditures of $1,000. Going forward, annual capital expenditures are projected to average $11,000 in the pro forma period. This improves the Company's ability to produce free cash flows.